Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination

Vaccine

Volumn 30, Issue 19, 2012, Pages 2943-2950

  Klade, Christoph S ^b   Schuller, Elisabeth ^b   Boehm, Thomas ^b   von Gabain, Alexander ^b   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INTERCELL AG   (Austria)

Author keywords

IC41 peptide vaccine; Therapeutic HCV vaccination

Indexed keywords

HEPATITIS C VACCINE; HLA A2 ANTIGEN; IC41 PEPTIDE VACCINE; IMIQUIMOD; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SKIN DISEASE; SKIN INDURATION; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AMINOQUINOLINES; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES; VIRAL LOAD; YOUNG ADULT;

EID: 84859436059     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.070     Document Type: Article

References (26)

1. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20(1):1-16.
2. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567.
3. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 1998, 28(6):939-944.
4. Management of Hepatitis C: 2002. In: Consensus Development Conference statement, National Institutes of Health Consensus Development Conference (2002 June 10-12). NIH Consensus Development Program. Available online: [accessed January 2010]. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm.
5. Brechot C. Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci 1996, 41(12 Suppl.):6S-21S.
6. Purcell R. The hepatitis C virus: overview. Hepatology 1997, 26(3 Suppl. 1):11S-14S.
7. Cerny A., Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999, 30(3):595-601.
8. Shin H., Wherry E.J. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 2007, 19(4):408-415.
9. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994, 91(16):7792-7796.
10. Prince A.M. Challenges for development of hepatitis C virus vaccines. FEMS Microbiol Rev 1994, 14(3):273-277.
11. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996, 93(26):15394-15399.
12. Dowd K.A., Hershow R.C., Yawetz S., Larussa P., Diaz C., Landesman S.H., et al. Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis 2008, 198(11):1651-1655.
13. Pestka J.M., Zeisel M.B., Bläser E., Schürmann P., Bartosch B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007, 104(14):6025-6030.
14. Lavillette D., Tarr A.W., Voisset C., Donot P., Bartosch B., Bain C., et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41(2):265-274.
15. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009, 8(3):333-345.
16. Strickland G.T., El-Kamary S.S., Klenerman P., Zeisel M.B., Baumert T.F. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8(6):379-386.
17. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006, 24(20):4343-4353.
18. Klade C.S., Wedemeyer H., Berg T., Buerger V., Jelovcan S., Lingnau K. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134(5):1385-1395.
19. Schlaphoff V., Klade C.S., Jilma B., Jelovcan S.B., Cornberg M., Tauber E. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007, 25(37-38):6793-6806.
20. Firbas C., Boehm T., Buerger V., Schuller E., Sabarth N., Jilma B. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 2010, 28(12):2397-2407.
21. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25(2):97-138.
22. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 1997, 186(6):859-865.
23. Hoofnagle J.H. A step forward in therapy for hepatitis C. N Engl J Med 2009, 360(18):1899-1901.
24. Wedemeyer H., Schuller E., Schlaphoff V., Stauber R.E., Wiegand J., Schiefke I., et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009, 27(37):5142-5151.
25. Korba B.E., Montero A.B., Farrar K., Gaye K., Mukerjee S., Ayers M.S., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008, 77(1):56-63.
26. Rossignol J.F., Elfert A., El-Gohary Y., Keeffe E.B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009, 136(3):856-862.